Overview
Cartalax (AED) is a synthetic three-amino-acid peptide bioregulator designed specifically to support joint cartilage and connective tissue.
What problem it targets: It is researched primarily for chronic joint stiffness, aching, and wear-and-tear caused by heavy training, repetitive impact, or natural aging. Rather than acting as a temporary pain blocker, Cartalax is used to help maintain joint integrity, improve daily comfort, and support long-term mobility.
What It Does
• Acts as a cellular "wake-up call" for cartilage: Unlike standard joint supplements (like glucosamine or collagen) that provide raw physical materials, Cartalax acts as an informational trigger. It enters connective tissue cells and interacts with DNA to signal dormant or aging cells to resume normal repair functions.
• Stimulates essential joint proteins: In laboratory studies on human stem cells, Cartalax significantly upregulated the genetic expression of SOX9, Type II collagen, and aggrecan—the exact building blocks required for healthy, shock-absorbing cartilage matrix.
• Balances cellular lifespan: Research shows it helps regulate apoptosis (programmed cell death), protecting vulnerable cartilage cells from dying off prematurely under stress.
• Realistic expectations: Cartalax helps optimize the cellular environment for cartilage maintenance and recovery, but it is not an overnight cure or a replacement for lost structural cartilage in bone-on-bone joints. In community research, it is typically cycled in short 10- to 20-day courses a few times per year rather than run year-round.
Reconstitution
| Vial Size | BAC Water / Solvent | Concentration |
|---|---|---|
| 20 mg (assumed vial strength) | 2 mL bacteriostatic water (requested mixing example) | 10 mg/mL = 10,000 micrograms/mL |
Reconstitution Calculator
Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.
Enter a target amount you already have and select the syringe capacity.
Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.
Presentation
20 mg vial used for the mixing example. Other sizes exist. Confirm the actual peptide content and sequence on the batch documentation.
Protocol
Community protocols & cycle timing
| Phase | Frequency | Amount | Notes |
|---|---|---|---|
| Common community cycle pattern | 10–20 consecutive days; a few courses per year with months between courses | Compound- and formulation-specific; see rows below | A shared cycle duration does not establish one shared dose. Oral labels may specify 30-day initial courses or 10-day maintenance courses. |
| Community-reported course | Daily; approximately 20 days at time of report | 2 mg | User reported concurrent BPC and TB use and heavy basketball training. Route and product quality were not verified. This is an anecdote, not a recommended regimen. |
Research study amounts
| Phase | Frequency | Amount | Notes |
|---|---|---|---|
| Human stem cells in culture | Replicative-ageing experiment; duration not stated in abstract | 200 ng/mL | 2023 cartilage-marker study. Cells were exposed in a laboratory; no human administration was tested. |
About these protocols
The community rows describe reported experience, not a standard or recommended human regimen. Product-label rows apply to the cited formulation; cell and animal rows describe research models. The 20 mg / 2 mL table is a concentration example using the requested assumptions. Solvent compatibility and stability are product-specific.
Sources
- Short peptide bioregulators — research overview
- Research paper — PubMed 37782646
- Research paper — PubMed 26033601
- Community discussion — the bioregulators youre sleeping on my top 3
- Community discussion — bioregulators explained the russian short
- Bioregulator courses and user experiences — Reddit
- Peptide bioregulators and course lengths — product guide
Handling & Stacking
- Bioregulators are often discussed as short 10–20-day courses, repeated a few times a year with months between courses, rather than continuous daily use.
- This describes a community cycle pattern, not one universal dose.
- Some finished oral products instead specify a 30-day course or 10-day maintenance course.
- Where users report subcutaneous administration, the abdomen or outer thigh are common subcutaneous sites.
- This does not establish an approved administration route for this compound.
- No compound-specific universal storage temperature or post-mixing stability period was verified.
- Use the supplier’s stability data for that formulation.
- Keep identity, lot, preparation date and final concentration traceable; a purity percentage alone does not establish sterility or stability.
- The named preparation is not established here as an approved treatment for its marketed goals.
- Approved alternatives depend on the diagnosed condition and cannot be assigned from an organ label alone.
